NCT05696314 (SPOT-US) is a NA clinical trial of Transoral Ultrasound in Oropharynx Cancer, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT05696314?

NCT05696314 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT05696314?

Interventions in NCT05696314: Transoral Ultrasound, Transcervical Ultrasound.

What condition does NCT05696314 study?

NCT05696314 studies Oropharynx Cancer, Tonsil Cancer, Base of the Tongue Tumor, Tonsil Hypertrophy, Tonsil Ulcer, Tonsil Neoplasm, Tonsil Lymphoma, Base of Tongue Carcinoma.

Is NCT05696314 still recruiting?

NCT05696314 is currently completed. Last updated 3 October 2024.

Last reviewed 2024-10-03 · How we verify

NCT05696314: SPOT-US

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx

Completed NA Last updated 3 October 2024

What this trial tests

NA trial testing Transoral Ultrasound in Oropharynx Cancer in 201 participants. Completed in 1 September 2024.

Timeline

1 February 2023

Primary endpoint
1 July 2024

1 September 2024

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	201
Start date	1 February 2023
Primary completion	1 July 2024
Estimated completion	1 September 2024
Sites	3 locations across Denmark

Drugs / interventions tested

Transoral Ultrasound
Transcervical Ultrasound

Conditions studied

Oropharynx Cancer — all drugs for Oropharynx Cancer →
Tonsil Cancer — all drugs for Tonsil Cancer →
Base of the Tongue Tumor — all drugs for Base of the Tongue Tumor →
Tonsil Hypertrophy — all drugs for Tonsil Hypertrophy →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Oropharynx Cancer or Tonsil Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to compare the sensitivity and specificity of transoral ultrasound, transcervical ultrasound, Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) in terms of detecting primary oropharynx tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of Transoral and Transcervical Ultrasonography with MRI for the Diagnostic Work-Up of Oropharynx Tumors: A Protocol for a Multicenter Clinical Trial (SPOTUS).
Garset-Zamani M, Hvilsom GB, Kjærgaard T, Plaschke CC, et al · · 2024 · cited 3× · PMID 38534997 · DOI 10.3390/diagnostics14060577

Verify or expand the search:

Other trials of Transoral Ultrasound

Trials testing the same drug.

NCT05841966 — Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary · NA · completed

Other recruiting trials for Oropharynx Cancer

Currently open trials in the same condition.

NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting
NCT06309225 — Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly · NA · recruiting
NCT06563362 — Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05696314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 3 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing